Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
attention, consecutive, Excellence, fourth, frequency, heighted, incidence, inherent, modification, NICE, nominal, ordinal, past, preclinical, produced, producing, promulgated, raw, refund, regular, reissued, remarkable, residual, run, safe, scale, Score, signaling, smaller, Stipulation, suggest, thereof, upcoming, Warning
Filing tables
Filing exhibits
Associated AMPE transcripts
AMPE similar filings
Filing view
External links
Exhibit 32.1
AMPIO PHARMACEUTICALS, INC.
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended September 30, 2020 (the “Report”) by Ampio Pharmaceuticals, Inc. (the “Company”), each of the undersigned hereby certifies to his knowledge that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Ay 10 | |
Dated: November 3, 2020 | /s/ Michael Macaluso |
| Michael Macaluso |
| Chairman and Chief Executive Officer |
|
|
Dated: November 3, 2020 | /s/ Daniel G. Stokely |
| Daniel G. Stokely |
| Chief Financial Officer and Secretary |